Status:
UNKNOWN
N-Acetyl Cystein and Contrast Nephropathy
Lead Sponsor:
Imam Khomeini Hospital
Collaborating Sponsors:
Tehran Heart Center
Conditions:
Chronic Kidney Disease Stage 2
Radiographic Contrast Agent Nephropathy
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
There are many controversies about the role of N-Acetyl Cystein in preventing of contrast nephropathy. These contradictory results may be due to different criteria for patients' selection, different e...
Detailed Description
Contrast Nephropathy is the third cause of acute kidney injury in hospitalized patients. The morbidity and mortality of this disorder is considerable. There is no treatment for this condition and all ...
Eligibility Criteria
Inclusion
- Age more than 18
- chronic Kidney disease stage 2-4
- use of nephrotoxins in last week leading to angiography
Exclusion
- Acute kidney injury
- concomitant use of other nephrotoxins
- need of repeated imaging with contrast in five days after the first surgery
- need for surgery in next five day after the contrast exposure
- need of using nephrotoxins in next five days after contrast exposure
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2014
Estimated Enrollment :
549 Patients enrolled
Trial Details
Trial ID
NCT01820195
Start Date
March 1 2013
End Date
November 1 2014
Last Update
March 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tehran Heart Center
Tehran, Iran